Loci specific epigenetic drug sensitivity
Abstract
Therapeutic targeting of epigenetic modulators offers a novel approach to the treatment of several diseases including cancer, heart diseases and AIDS. The cellular consequences of chemical compounds that target epigenetic regulators (epi-drugs) are complex. Epi-drugs affect global cellular phenotypes and cause local changes to gene expression due to alteration of a gene chromatin environment. Despite increasing use in the clinic, the mechanisms responsible for cellular changes are unclear. Specifically, to what degree the effects are a result of cell-wide changes or disease related locus specific effects is unknown. Here we developed a platform to systematically and simultaneously investigate the sensitivity of epi-drugs at hundreds of genomic locations by combining DNA barcoding, unique split-pool encoding and single cell expression measurements. Internal controls are used to isolate locus specific effects separately from any global consequences these drugs have. Using this platform we discovered wide-spread loci specific sensitivities to epi-drugs for three distinct epi-drugs that target histone deacetylase, DNA methylation and bromodomain proteins. By leveraging ENCODE data on chromatin modification, we identified features of chromatin environments that are most likely to be affected by epi-drugs. The measurements of loci specific epi-drugs sensitivities will pave the way to the development of targeted therapy for personalized medicine.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 12
- FWCI
- 0.73
- Field percentile
- top 36%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Epigenomic manipulation reveals the relationship between locus specific chromatin dynamics and gene expression
Vrinda Venu, Eric M. Small, … Christina R. Steadman·Epigenetics & ChromatinPeer-reviewed·Oct 3, 2025
- Predicting gene expression changes upon epigenomic drug treatment
Piyush Agrawal, Vishaka Gopalan, Sridhar S. Hannenhalli·F1000ResearchPeer-reviewed·Dec 19, 2023
- The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity
A. J. Ohnmacht, A. Rajamani, … M. P. Menden·bioRxiv·Jun 1, 2023
- Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia
Laura Corveleyn, Lien Provez, … Maarten Dhaenens·Scientific ReportsPeer-reviewed·Mar 26, 2026
- EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
O. Yedier-Bayram, B. Gokbayrak, … T. Bagci-Onder·bioRxiv·May 14, 2021
- Altered chromatin accessibility and nucleosome positioning landscape upon HDAC and LSD1 inhibition in cancer cell
Sagnik Sen, Pierre Olivier Esteve, … Sriharsa Pradhan·bioRxiv·Apr 11, 2026